Results 21 to 30 of about 1,651 (123)

Oritavancin polymethylmethacrylate (PMMA)—compressive strength testing and in vitro elution

Journal of Orthopaedic Surgery and Research, 2019
Background Polymethylmethacrylate (PMMA) is used for local antimicrobial delivery in orthopedic infection. Oritavancin is a long half-life lipoglycopeptide with broad activity against Gram-positive bacteria.
Suzannah M. Schmidt-Malan, Kerryl E. Greenwood-Quaintance, Lawrence J. Berglund, Jayawant Mandrekar, Robin Patel   +4 more
doaj   +1 more source

Expediting Discharge in Hospitalized, Adult Patients with Skin and Soft Tissue Infections Who Received Empiric Vancomycin Therapy with Oritavancin: Description of Findings from an Institutional Pathway

Drugs - Real World Outcomes, 2020
Background An internal quality assurance review at AtlantiCare Regional Medical Center (ARMC) revealed that patients admitted with skin and soft tissue infections (SSTIs) remained in hospital post-resolution of acute symptoms and demonstrated a delayed ...
Cristen Whittaker, Thomas P. Lodise, Ethan Nhan, Joseph Reilly   +3 more
doaj   +1 more source

Early Directed Oritavancin Therapy in the Emergency Department May Lead to Hospital Avoidance Compared to Standard Treatment for Acute Bacterial Skin and Skin Structure Infections: A Real-World Retrospective Analysis

Drugs - Real World Outcomes, 2020
Objectives Acute bacterial skin and soft tissue infections (ABSSSIs) are a leading cause of presentation to the emergency department (ED). This study aimed to determine the potential impact of utilizing oritavancin in the ED or observation unit (OBS) on ...
Brittany Helton, Ashley MacWhinnie, Sarah Brooks Minor, Thomas P. Lodise, Kelly D. Rafferty, Steven L. Allison   +5 more
doaj   +1 more source

Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin: A Two-Year, Multicenter, Retrospective Study

Drugs - Real World Outcomes, 2020
Background Acute osteomyelitis is typically caused by Gram-positive pathogens, commonly antibiotic-resistant Staphylococcus species. Standard antibiotic treatment is challenging due to required multiple daily doses, therapeutic drug monitoring, and ...
Nicholas W. Van Hise, Vishnu Chundi, Vishal Didwania, Michael Anderson, David McKinsey, Ingrid Roig, Akhilesh Sharma, Russell M. Petrak   +7 more
doaj   +1 more source

Comparative Activity of Lipoglycopeptide Antibiotics Against Gram-Positive Bacteria

Антибиотики и Химиотерапия, 2022
Lipoglycopeptide antibiotics are semi-synthetic derivatives of glycopeptides and are characterized by a pronounced bactericidal activity against gram-positive pathogens.
V. V. Gostev, O. S. Sulian, O. S. Kalinogorskaya, L. N. Popenko, A. N. Kruglov, S. A. Gordeeva, E. V. Nesterova, D. P. Gladin, N. N. Trophimova, P. S. Chulkova, I. V. Ageevets, V. A. Ageevets, T. V. Chernenkaya   +12 more
doaj   +1 more source

A Two-Dose Oritavancin Regimen Using Pharmacokinetic Estimation Analysis

Drugs - Real World Outcomes, 2020
Background Antibiotics for the treatment of complicated, multidrug-resistant Gram-positive infections are limited, especially when prolonged treatment is necessary.
Warren E. Rose, Paul R. Hutson
doaj   +1 more source

Oritavancin for the treatment of complicated gram-positive infection in persons who inject drugs

BMC Pharmacology and Toxicology, 2020
Background Treatment of complicated infections in persons who inject drugs (PWID) and patients experiencing homelessness poses a unique challenge to clinicians.
Aileen Ahiskali, Heather Rhodes
doaj   +1 more source

Role of Oritavancin in the Treatment of Infective Endocarditis, Catheter- or Device-Related Infections, Bloodstream Infections, and Bone and Prosthetic Joint Infections in Humans: Narrative Review and Possible Developments

Life, 2023
Oritavancin is a long-acting lipoglycopeptide with in vitro activity against Gram-positive pathogens, as well as good bactericidal activity and sterilisation ability in biofilm. It has been approved for acute bacterial skin and skin structure infections (
Tommaso Lupia, Ilaria De Benedetto, Roberta Bosio, Nour Shbaklo, Francesco Giuseppe De Rosa, Silvia Corcione   +5 more
doaj   +1 more source

The Clinical Efficacy of Multidose Oritavancin: A Systematic Review

Antibiotics, 2023
Oritavancin (ORI) is a semisynthetic lipoglycopeptide approved as a single 1200 mg dose intravenous infusion for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) caused by Gram-positive organisms in adults.
Giammarco Baiardi, Michela Cameran Caviglia, Fabio Piras, Fabio Sacco, Roberta Prinapori, Maria Luisa Cristina, Francesca Mattioli, Marina Sartini, Emanuele Pontali   +8 more
doaj   +1 more source

Successful treatment of a prosthetic hip infection due to Enterococcus faecalis with sequential dosing of oritavancin and prosthesis preservation without prosthetic joint surgical manipulation

IDCases, 2020
A patient with a prosthetic joint infection (PJI) complicated with deep surgical site infection due to vancomycin-susceptible Enterococcus faecalis. The initial treatment consisted of 10 days with daptomycin plus ampicillin.
Jullian P. Nguyen, Brian X. Contreras, Miguel Sierra-Hoffman, Kim Saddler, Mark L. Stevens, Miriams T. Castro-Lainez, Brett Knox, Rafael J. Deliz   +7 more
doaj   +1 more source